7 completed, 3 unknown, 2 not yet recruiting, 1 active not recruiting. 5 Not applicable, 3 Phase 1, 3 Phase 2, 2 Phase 3.
Follow T2D: new trials by email Literature Review of T2D trials Research Report on T2D
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Adding Acetazolamide on Top of SGLT2 Inhibition in Persons With Type 2 Diabetes Acetazolamide 62.5 mg, Acetazolamide 125 mg, Acetazolamide 250 mg - T2D | Phase 2 | Not yet recruiting | University Health Network, Toronto | 20 | 2026-12-01 | 2026-10-29 |
| Potatoes, Type 2 Diabetes, and Cardiometabolic Health Controlled diet: Potato-rich healthy dietary pattern, Controlled diet: Typical Western-style dietary pattern - T2D, Blood Pressure | Not applicable | Recruiting | Virginia Polytechnic Institute and State University | 42 | 2026-08-27 | 2026-09-03 |
| Bioequivalence Study of GZR4 Injection With Different Manufacturing Processes in Healthy Adult Participants GZR4 injection A, GZR4 injection B - T2D | Phase 1 | Not yet recruiting | Gan & Lee Pharmaceuticals. | 64 | 2026-07-01 | 2026-06-26 |
| Fitbit and AI Chatbot in Sedentary Primary Care Patients With T2D Fitbit and AI Chatbot, Routine Care - Type 2 Diabetes, Type 2 Diabetes Mellitus (T2DM) | Completed | University of Colorado, Denver | 35 | 2025-09-03 | 2026-08-19 | |
| Embecta AID System in Adults With Type 2 Diabetes An AID System., Standard of Care (SC) - Type 2 Diabetes, Type 2 Diabetes Mellitus (T2DM) | Not applicable | Withdrawn | Embecta Corp. | 2025-01-01 | 2024-12-16 | |
| Clinical Study on Exploring High Risk Factors Inducing the Progress of Diabetes T2D | Unknown | Peking University Third Hospital | 90 | 2024-05-20 | 2024-03-15 | |
| A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes Tirzepatide, Placebo - Overweight, Obesity | Phase 2 | Completed | Eli Lilly and Company | 134 | 2023-02-08 | 2026-09-11 |
| A Study of Insulin Efsitora Alfa (LY3209590) Compared to Glargine in Adult Participants With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time (QWINT-1) Insulin Efsitora Alfa, Insulin Glargine - Type 2 Diabetes, T2D | Phase 3 | Completed | Eli Lilly and Company | 795 | 2023-01-14 | 2025-08-06 |
| Study on the Efficacy and Safety of Chiglitazar Sodium in PCOS With T2DM pioglitazone group: lifestyle intervention+ metformin+ orlistat (obese patients)+ pioglitazone, the Chiglitazar group: lifestyle intervention+ metformin+ orlistat (obese patients)+ Chiglitazar - PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries, T2D | Phase 1 | Unknown | Affiliated Hospital of Nantong University | 142 | 2022-10-01 | 2023-08-01 |
| A Study to Evaluate Tirzepatide (LY3298176) in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin or Basal Insulin or Both Tirzepatide Dose 1, Tirzepatide Dose 2, Placebo - Type2 Diabetes, Diabetes Mellitus | Phase 3 | Completed | Eli Lilly and Company | 99 | 2022-04-13 | 2025-09-26 |
| The Role of Traditional or Western Diet in the TBC1D4 Gene on Glucose Homeostasis in Greenland Inuits Cross-over study - T2D | Not applicable | Completed | University of Copenhagen | 64 | 2019-04-15 | 2020-11-25 |
| Prevalence of NAFLD in T2DM Patients FibroScan - NAFLD, T2D | Not applicable | Active not recruiting | Ziekenhuis Oost-Limburg | 385 | 2019-03-01 | 2025-12-02 |
| Peanut Consumption and Cardiovascular Disease Risk in a Chinese Population Peanut, Control - T2D | Not applicable | Completed | Harvard School of Public Health (HSPH) | 238 | 2017-10-24 | 2019-02-28 |
| Pathogenesis of Youth Onset Type 2 Diabetes and Prediabetes Oral Glucose Tolerance Test, Hyperglycemic Clamp, Isoglycemic Intravenous Glucose Test - IGT - Impaired Glucose Tolerance, T2D | Completed | Yale University | 100 | 2017-03-01 | 2023-02-23 | |
| BM-MNC and UCMSC for Type 2 Diabetes Mellitus Patients Bone-marrow aspiration, Intra-pancreatic Catheterisation of BM-MNC, Intravenous Infusion of UC-MSC - T2D | Phase 1 / Phase 2 | Unknown | Universitas Indonesia | 15 | 2016-03-14 | 2020-08-06 |
Diabetes Mellitus, Type 2 (7) · Diabetes Mellitus (1) · Endocrine System Diseases (1) · Glucose Intolerance (1) · Glucose Metabolism Disorders (1) · Metabolic Diseases (1) · Motor Activity (1) · Non-alcoholic Fatty Liver Disease (1) · Obesity (1) · Overweight (1) · Polycystic Ovary Syndrome (1) · Renal Insufficiency, Chronic (1)
Nutritional and Metabolic Diseases (8) · Endocrine System Diseases (7) · Glucose Metabolism Disorders (7) · Metabolic Diseases (7) · Diabetes Mellitus (6) · Female Urogenital Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2) · Urogenital Diseases (2) · Adnexal Diseases (1) · Behavior (1) · Body Weight (1) · Chronic Disease (1) · Cysts (1) · Digestive System Diseases (1) · Disease Attributes (1)
Acetazolamide (1) · Cross-Over Studies (1) · Glucose Tolerance Test (1) · Insulin Glargine (1) · Standard of Care (1) · Tirzepatide (1) · dapagliflozin (1)
Eli Lilly and Company (3) · Affiliated Hospital of Nantong University (1) · Embecta Corp. (1) · Gan & Lee Pharmaceuticals. (1) · Harvard School of Public Health (HSPH) (1) · Peking University Third Hospital (1) · Universitas Indonesia (1) · University Health Network, Toronto (1) · University of Colorado, Denver (1) · University of Copenhagen (1) · Virginia Polytechnic Institute and State University (1) · Yale University (1) · Ziekenhuis Oost-Limburg (1)
United States (7) · China (3) · Mexico (3) · Canada (2) · Denmark (2) · Argentina (1) · Australia (1) · Austria (1) · Belgium (1) · Brazil (1) · France (1) · India (1) · Indonesia (1) · Israel (1) · Italy (1)
David Z.I Cherney, MD CM, PhD, FRCPC (1) · Dennis Cladis, PhD (1) · Mathieu Struyve, MD (1) · Rayhan Lal, M.D. (1) · Seth Kramer, DO, MPH (1) · Sonia Caprio, MD (1) · Xiaoran Liu, PhD (1)
PMID 26794657, PMID 31214172, PMID 33236043, PMID 33604488, PMID 39963952, PMID 40512543, PMID 40548694, PMID 40975112, PMID 41591636
2023 (1), R01DK111038 (1)